liver disease

Shilpa Secures SEC, CDSCO Approval for New IND Tablets in NAFLD

Shilpa Medicare has received approval from India’s top drug authorities to move forward with its new IND - Nor-Ursodeoxycholic Acid (500 mg).

Gilead to Buy Liver Drugmaker CymaBay for $4.3 Billion

US biopharmaceutical company Gilead Sciences is to acquire CymaBay Therapeutics for $4.3 billion. Gilead offered to purchase all outstanding shares of CymaBay for $32.50 per share in cash.

Novartis Takes Rights to Conatus NASH Drug